AU2001246237A1 - Process and composition for cleaning medical instruments - Google Patents
Process and composition for cleaning medical instrumentsInfo
- Publication number
- AU2001246237A1 AU2001246237A1 AU2001246237A AU4623701A AU2001246237A1 AU 2001246237 A1 AU2001246237 A1 AU 2001246237A1 AU 2001246237 A AU2001246237 A AU 2001246237A AU 4623701 A AU4623701 A AU 4623701A AU 2001246237 A1 AU2001246237 A1 AU 2001246237A1
- Authority
- AU
- Australia
- Prior art keywords
- composition according
- quat
- biocide
- enzyme
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims description 87
- 238000004140 cleaning Methods 0.000 title claims description 29
- 238000000034 method Methods 0.000 title claims description 20
- 230000008569 process Effects 0.000 title description 3
- 230000003115 biocidal effect Effects 0.000 claims description 74
- 102000004190 Enzymes Human genes 0.000 claims description 70
- 108090000790 Enzymes Proteins 0.000 claims description 70
- 229940088598 enzyme Drugs 0.000 claims description 70
- 239000003139 biocide Substances 0.000 claims description 60
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 claims description 59
- 239000000645 desinfectant Substances 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 229910052796 boron Inorganic materials 0.000 claims description 25
- 230000000694 effects Effects 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 230000001012 protector Effects 0.000 claims description 20
- 238000010790 dilution Methods 0.000 claims description 18
- 239000012895 dilution Substances 0.000 claims description 18
- -1 hydrazes Proteins 0.000 claims description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- 239000012141 concentrate Substances 0.000 claims description 14
- 239000003381 stabilizer Substances 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 239000000693 micelle Substances 0.000 claims description 11
- 229920005862 polyol Polymers 0.000 claims description 11
- 150000003077 polyols Chemical class 0.000 claims description 11
- 230000000087 stabilizing effect Effects 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 9
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 150000001639 boron compounds Chemical class 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 7
- 239000002736 nonionic surfactant Substances 0.000 claims description 7
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 7
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 229910021538 borax Inorganic materials 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000004328 sodium tetraborate Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 108010065511 Amylases Proteins 0.000 claims description 4
- 102000013142 Amylases Human genes 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 150000003868 ammonium compounds Chemical class 0.000 claims description 4
- 235000019418 amylase Nutrition 0.000 claims description 4
- 229940025131 amylases Drugs 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 150000001860 citric acid derivatives Chemical class 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 239000011929 di(propylene glycol) methyl ether Substances 0.000 claims description 3
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- GDTSJMKGXGJFGQ-UHFFFAOYSA-N 3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound O1B([O-])OB2OB([O-])OB1O2 GDTSJMKGXGJFGQ-UHFFFAOYSA-N 0.000 claims description 2
- 229910011255 B2O3 Inorganic materials 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- 108010053835 Catalase Proteins 0.000 claims description 2
- 102000016938 Catalase Human genes 0.000 claims description 2
- 102000005575 Cellulases Human genes 0.000 claims description 2
- 108010084185 Cellulases Proteins 0.000 claims description 2
- 108090000371 Esterases Proteins 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 108700020962 Peroxidase Proteins 0.000 claims description 2
- 102000003992 Peroxidases Human genes 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 125000002015 acyclic group Chemical group 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- IUHDTQIYNQQIBP-UHFFFAOYSA-M benzyl-ethyl-dimethylazanium;chloride Chemical compound [Cl-].CC[N+](C)(C)CC1=CC=CC=C1 IUHDTQIYNQQIBP-UHFFFAOYSA-M 0.000 claims description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 claims description 2
- 150000001642 boronic acid derivatives Chemical class 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Chemical group 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 108010089934 carbohydrase Proteins 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- JKWMSGQKBLHBQQ-UHFFFAOYSA-N diboron trioxide Chemical compound O=BOB=O JKWMSGQKBLHBQQ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 235000011073 invertase Nutrition 0.000 claims description 2
- 150000003893 lactate salts Chemical class 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims description 2
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 claims description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims description 2
- 239000003352 sequestering agent Substances 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 150000003892 tartrate salts Chemical class 0.000 claims description 2
- HOSGXJWQVBHGLT-UHFFFAOYSA-N 6-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical group N1C(=O)CCC2=CC(O)=CC=C21 HOSGXJWQVBHGLT-UHFFFAOYSA-N 0.000 claims 1
- 240000008791 Antiaris toxicaria Species 0.000 claims 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical group [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims 1
- 125000005619 boric acid group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- XXBDWLFCJWSEKW-UHFFFAOYSA-N dimethylbenzylamine Chemical compound CN(C)CC1=CC=CC=C1 XXBDWLFCJWSEKW-UHFFFAOYSA-N 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 150000004675 formic acid derivatives Chemical class 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 239000012137 tryptone Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 description 48
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 23
- 235000010633 broth Nutrition 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000011084 recovery Methods 0.000 description 13
- 238000004659 sterilization and disinfection Methods 0.000 description 13
- 239000002609 medium Substances 0.000 description 11
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 10
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 10
- 239000008233 hard water Substances 0.000 description 10
- 235000008504 concentrate Nutrition 0.000 description 8
- 238000011109 contamination Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000000249 desinfective effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 239000002689 soil Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108090000787 Subtilisin Proteins 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 230000009849 deactivation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010029803 Nosocomial infection Diseases 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000003206 sterilizing agent Substances 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- WBIQQQGBSDOWNP-UHFFFAOYSA-N 2-dodecylbenzenesulfonic acid Chemical compound CCCCCCCCCCCCC1=CC=CC=C1S(O)(=O)=O WBIQQQGBSDOWNP-UHFFFAOYSA-N 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000000937 inactivator Effects 0.000 description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical group [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 235000014666 liquid concentrate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000847 nonoxynol Polymers 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000008379 phenol ethers Chemical class 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000005270 trialkylamine group Chemical group 0.000 description 2
- SHRGCOIDGUJGJI-UHFFFAOYSA-N 1-(3-methoxypropoxy)propan-1-ol Chemical compound CCC(O)OCCCOC SHRGCOIDGUJGJI-UHFFFAOYSA-N 0.000 description 1
- CUDYYMUUJHLCGZ-UHFFFAOYSA-N 2-(2-methoxypropoxy)propan-1-ol Chemical compound COC(C)COC(C)CO CUDYYMUUJHLCGZ-UHFFFAOYSA-N 0.000 description 1
- IEORSVTYLWZQJQ-UHFFFAOYSA-N 2-(2-nonylphenoxy)ethanol Chemical compound CCCCCCCCCC1=CC=CC=C1OCCO IEORSVTYLWZQJQ-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- RNMDNPCBIKJCQP-UHFFFAOYSA-N 5-nonyl-7-oxabicyclo[4.1.0]hepta-1,3,5-trien-2-ol Chemical compound C(CCCCCCCC)C1=C2C(=C(C=C1)O)O2 RNMDNPCBIKJCQP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000006154 MacConkey agar Substances 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- JNGWKQJZIUZUPR-UHFFFAOYSA-N [3-(dodecanoylamino)propyl](hydroxy)dimethylammonium Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)[O-] JNGWKQJZIUZUPR-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000006177 alkyl benzyl group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- OCBHHZMJRVXXQK-UHFFFAOYSA-M benzyl-dimethyl-tetradecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 OCBHHZMJRVXXQK-UHFFFAOYSA-M 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002599 biostatic effect Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000223 dermal penetration Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical group CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960001922 sodium perborate Drugs 0.000 description 1
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
- A01N33/02—Amines; Quaternary ammonium compounds
- A01N33/12—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/38—Cationic compounds
- C11D1/62—Quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38618—Protease or amylase in liquid compositions only
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38627—Preparations containing enzymes, e.g. protease or amylase containing lipase
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38636—Preparations containing enzymes, e.g. protease or amylase containing enzymes other than protease, amylase, lipase, cellulase, oxidase or reductase
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38645—Preparations containing enzymes, e.g. protease or amylase containing cellulase
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- C11D2111/20—
Description
PROCESS AND COMPOSITION FOR CLEANING MEDICAL INSTRUMENTS
FIELD OF THE INVENTION:
This invention relates to a method of and composition for cleaning medical instruments. The method is suitable for use with endoscopes and is herein described with particular reference to that use, but it will be understood that the method is equally suitable for use with other instruments such as colonoscopes, laparascopes, other surgical, medical, biopsy, dental and such like instruments, parts of such instruments and similar paraphernalia (hereinafter collectively referred to as "medical instruments"). The invention is also applicable for treatment of instruments which are required merely to be disinfected for example hair-dressing tools, certain beauty parlour equipment, and the like.
BACKGROUND ART Endoscopes are increasingly being used in medical diagnosis and therapy When used as directed the endoscope becomes grossly soiled and massively infected with microorganisms which are present in body cavities, on the mucous membrane, and in the blood. Accordingly the instruments must be thoroughly cleaned and disinfected after each use. Endoscopes are precision instruments which are made from a combination of materials. They are difficult to clean in view of the sensitivity of the materials involved to chemical attack and because they have narrow lumens making access to and cleaning of interior surfaces difficult.
Until the last decade, it was common for soiled instruments to be placed on a towel or in a covered pan until they were sent to a centralised service where they were scrubbed, washed and either steriiised in a steam autoclave (if not heat sensitive) or chemically (e.g. with formaldehyde). In the last decade, there has arisen a particular concern to avoid transmission of very serious and sometimes fatal diseases such as may be carried in blood and tissue, for example hepatitis B, HIV, and other infections.
Nowadays, contaminated endoscopes and other medical instruments are typically treated in a first bath ("presoak" or "cleaning" bath) containing one or a combination of anionic and non ionic surfactants. The first bath may optionally include one, or a combination of enzymes, adapted to digest biological contaminants including cellular material, blood and other body fluids. Enzyme containing pre-soaking liquids are significantly more efficient in removing water insoluble and protein soils and are now considered the industry standard. In the case of surgical instruments requiring to be sterilised, the instruments are typically then removed from the first bath, washed free of enzyme solution and other residues, and then deposited in a second bath containing a chemical sterilizing agent (for example, gluteraldehyde). The first bath container is subsequently washed and then furnished with a fresh enzyme solution so that the process may be repeated. The necessity for separate cleaning and sterilizing baths arises since enzymes are denatured by all known sterilizing agents and since sterilizing agents are deactivated by enzymes (as enzymes are proteins). Accordingly it has to date proved impossible to provide a "single bath" cleaning and sterilizing treatment, although a two part system involving an enzyme treatment followed by addition of a phenolic disinfectant in the same bath has been proposed.
Sterilisation protocols are followed to prevent cross infection and therefore instruments used with one patient are not combined with those which may have been used with another in the presoak bath. It is noteworthy that the
presoak is not passive. Staff are instructed to syringe detergent liquor through all the lumens, to brush biopsy channels, etc. A colonoscope requires up to 14 manual brushing - syringing - plugging - unplugging operations. It is usual for staff to wear latex gloves when handling instruments into or out of the baths and when performing such like operations.
The present inventor has observed that currently used procedures, while effective for preventing crossinfection between patients, in fact exposes medical and/or hospital staff to hitherto unrecognised health and safety risks. By virtue that the enzymes of the first bath digest the biological secretions holding the microorganisms, thus releasing them within the bath, and surfactants efficiently disperse them, the fluid content of the first bath is itself readily contaminated to high levels with infectious material. Contrary to the belief of some hospital staff, enzymes do not kill bacteria but rather release them. The present inventor has measured bacterial counts in excess of 1 x 109 colony forming units ("cfu") per sq. cm. on instruments entering the first bath
Staff are therefore at risk of infection (i) from splashes from the first bath either during scrubbing to release contaminants or during draining the first bath (or from splashes if an instrument is accidentally dropped into the bath), (ii) from glove failures (latex gloves have a "pinhole" failure rate of about 12%), (iii) from accidental glove immersion above the wrist line, (iv) from finger stick incidents in the bath resulting in glove and sometimes dermal penetration, (v) from aerosols created by brushes and syringes. In addition the wall surface of the first bath remains contaminated after the bath has been emptied and if not itself disinfected may be handled by unprotected staff. The last mentioned risk may be minimised by performing the sterilisation step immediately after the digestion step in the same container, but this does not avoid any of the other hitherto unrecognised risks and is wasteful in use of excess sterilant.
ln some cases instruments may not be required to be sterilised, for example with spatulas, and holders which do not penetrate the body tissue, hair dressing implements and the like, it may be sufficient to disinfect the instruments to an appropriate standard. In such cases it would be desirable to provide a cleaning and disinfecting treatment capable of meeting the required standards with a single composition.
Any discussion of the prior art herein is not to be construed as indicative of the state of the common general knowledge in the field.
It is the object of the invention to avoid or ameliorate the above discussed disadvantages of prior art, or at least provide a commercial alternative to the prior art.
It is an object of preferred embodiments of the present invention to avoid or at least ameliorate the risk of infection to persons cleaning medical instruments by such procedures.
It is a further object of at least some of the preferred embodiments to provide a single step cleaning and disinfecting composition for use in cleaning medical instruments.
Preferred embodiments of the invention also address the risk of cross infection of instruments by virtue of multiplication of microorganisms, if any, which remain on the bath walls after each cycle of instrument cleaning.
It is an object of some embodiments of the invention to provide simple means for cleaning and disinfecting surfaces which require to be disinfected
BRIEF DESCRIPTION OF THE INVENTION
According to a first aspect the invention provides a system for cleaning a contaminated medical instrument including the step of treating the instrument
with a solution containing an enzyme based cleaning composition and a "hospital grade disinfectant" (as herein defined).
Unless the context clearly requires otherwise, throughout the description and the claims, the words 'comprise', 'comprising', and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".
In preferred embodiments of the invention the treating step includes immersion of the instrument in the solution and is followed by a second treatment in which the instrument is sterilised. However for some disinfecting purposes it may be sufficient to rinse the instrument with sterile water after the first treatment or to provide a further disinfecting treatment.
In Australia, disinfectants are graded according to tests specified by the TGA in order of decreasing efficacy as Grade B "Hospital Dirty", Grade A "Hospital Clean", Grade C "household/commercial". A copy of "The TGA Disinfectant Test" is annexed. The TGA tests are specified as TGO 54. Similar tests and classifications are applicable in other countries. The term "hospital grade" disinfectant" is herein used to refer to disinfectants passing the Grade A test, i.e. a "hospital grade" disinfectant must be at least Hospital Grade A
The applicant has discovered a method whereby a hospital grade disinfectant, preferably a quaternary ammonium biocide ("quat. biocide") can be included in a cleaning composition which in use comes in contact with proteinatious material such as blood and other biological contaminants such as are encountered in cleaning endoscopes and other surgical instruments.
Hitherto it has been accepted that quat. biocides are instantaneously deactivated by protein and certain ions such as those found in hard water. It is therefore surprising that a grade A disinfectant can be effective in such an environment as is made possible by the present invention. Even more surprisingly, in preferred embodiments of the invention the quat. biocide is in
the form of a liquid concentrate which retains its biocidal activity in prolonged shelf-storage in contact with one or more enzymes which are also proteins which normally would be expected to quickly deactivate the quat. biocide. Surprisingly, also, the enzymes are not irreversibly denatured. The liquid concentrate is readily diluted with water for use.
It will be appreciated that a first treatment according to the invention does not result in disinfection or sterilisation of the instruments and for that purpose a subsequent disinfection or sterilizing treatment may be required. However the presence of an effective disinfectant in the enzyme bath is sufficient to prevent multiplication of microorganisms in the bath and to afford a degree of protection for staff not previously available from accidental infection in the risk circumstances previously outlined.
According to a second aspect the present invention provides a system for cleaning contaminated medical instruments and the like wherein the instruments are subjected to treatment with a composition including: at least one enzyme; a quaternary ammonium biocide, and an "activity protector" in a concentration sufficient to maintain a biocidal efficacy of the quaternary ammonium biocide in the presence of the at least one enzyme and an additional protein load.
The "activity protector" is described more particularly hereinafter
In highly preferred embodiments, compositions according to the second aspect also include: a non-ionic surfactant;
Desirably the " activity protector" or "activity protector" system is present in a concentration sufficient that the quaternary ammonium biocide is effective in use to provide "hospital grade A" disinfection (as herein defined) of the bath in
the presence of the at least one enzyme and of a typical proteinaceous load in the bath.
The "activity protector" is a composition selected from (1 ) compositions known to be effective in stabilizing enzymes in liquid aqueous solutions, including enzyme stabilizing compounds and systems, (2) selected "micelle inhibitors", and mixtures of (1 ) and (2). In preferred embodiments of the invention the "activity protector" is an enzyme stabilizer and more particularly is a suitable concentration of boron anions. Desirably these are solvated in a polyol and may be combined with enzyme stabilizing synergists or adjuvants forming an enzyme stabilizing system. Preferred "micelle inhibitors" include species known to modify as well as to inhibit micelle formation and may be selected from water miscible solvents such as C1 - C6 alkanols, C1 - C6 diols, C2 - C24 alkylene glycol ethers, alkylene glycol alkyl ethers, and mixtures thereof.. ,A highly preferred micelle inhibitor is di - (propylene glycol) methyl ether.fDPM") and analogues thereof which modify micelle formation. It is especially preferred to combine the use of borate ions with DPM which has been found by the present inventor synergistically to enhance the biocidal activity protection conferred on the quat. biocide without irreversibly denaturing the enzyme.
It is highly preferred that the quat biocide is an aryl quat compound, preferably benzalkonium halide.
It is well known that enzymes may become denatured in storage, in the presence of other enzymes, and/or in the presence of antagonistic anions such as for example anionic surfactants, quaternary ammonium compounds and detergency "builders". A number of enzyme stabilizing systems have been developed and are well known in the enzyme formulation art. An example of an "enzyme stabilizing system" is a boron compound (e.g. boric acid ) which in the past has been used alone or with selected other adjuvants and or synergists (e.g. polyfunctional amino compounds, antioxidants, etc) to protect proteolytic and other enzymes in storage and in various products. It
has been theorised that an enzyme stabilizing system such as boron and calcium form intramolecular bonds which effectively cross-link or staple an enzyme molecule so as to hold it in its active spatial configuration. Enzyme stabilizers have not hitherto been used to protect the biocidal activity of a quat. biocide. The present invention is based on the surprising discovery that at least some enzyme stabilizing systems are effective in protecting the biocidal activity of quat. biocides in the presence of protein.
In accord with the present invention the ratio of "activity protector" e.g. boron to quat. biocide is preferably chosen to substantially to minimise the Minimum Inhibitory Concentration ("MIC") of quat. biocide in the presence of the enzymes in the formulation and at a given level of protein load. MIC is a measure of the minimum concentration of the biocide which succeeds in preventing bacterial growth in a culture during a specified time period, for example 24 hrs.. Details of the MIC test are shown in "Bailey & Scott
'Diagnostic Microbiology', 8th edition, 1990 at page 177. The TGA tests are specified at TGO 54 annexed. MIC tests referred to herein are conducted over 24 hrs
In the present case in which an enzyme is present in addition to the quat. biocide and in which it is desired to retain the enzymatic activity of the enzyme as well as the biocidal activity of the quat, biocide then the quantity of "activity protector" required will need to be greater than that required merely to protect the enzyme and will need to be sufficient both to stabilise the enzyme and protect the biocidal activity of the quat. biocide. Moreover as the composition is anticipated to come into contact with an external proteinaceous load (from contaminants in the surgical instruments bath) then the "activity protector" concentration will need to be greater still
The inventor has discovered that boron surprisingly protects a quaternary biocide from deactivation by a protein in such a way and to such an extent that the MIC of the biocide is not increased in the presence of a protein. In preferred embodiments of the invention the MIC is dramatically reduced, for
example, more than halved notwithstanding the presence of up to 2 wt.% based on the weight of solution, of protein. This allows the formulation of a wide range of new and useful compositions which remain effective as disinfectants or antibacterials in circumstances in which the prior art would be significantly less effective or not effective at all.
The invention also enables storage-stable liquid biocidally effective compositions to be prepared with a lower concentration of quat. biocide and at much lower cost. By "shelf stable" is meant that the composition retains at least 50% of its biocidal efficacy after 12 months storage in a sealed container at 18 - 25 °C. Preferred embodiments of the invention retain better than 98% biocidal efficacy under these conditions.
Without wishing to be bound by theory, the inventor speculates that polymeric borate ions associate with the cationic quat. biocide, thus protecting the quat biocide from combining with proteins. When the formulation is diluted the polymeric ions become unstable and release the quat biocide for disinfection. Alternatively, it may be that the biocidal activity of the quat. biocide significantly relates to denaturing proteins of cell membranes and that boron complexes with charged groups of non-living proteins and prevents wasting quat. on denaturing non-living proteins. However as enzymes are structurally quite different from quat. biocides, and as the complete mechanism by which quat. biocides kill bacteria is also uncertain, it was not previously predictable that any enzyme stabilizer would be effective in maintaining the biocidal activity of a quat. biocide (an enzyme antagonist). The mechanism by which the activity of the quat biocide is maintained may be different from that whereby the enzyme is stabilised.
Other "activity protectors" are discussed hereinafter.
According to a third aspect the invention provides a composition according to the second aspect further including a nonionic surfactant.
Preferably the nonionic surfactant is one or a combination of surfactants selected from the group consisting of ethoxylates or propoxylates and block copolymer of these.
A highly preferred embodiment of the invention, provides an economical effective cleaning and disinfecting composition which contains enzymes, is shelf stable in storage in concentrated form, is readily diluted to a working concentration and remains biocidal in use in the presence of protein. Desirably the working dilution is effective in use as a Hospital Grade A disinfectant.
BEST MODE OF PERFORMING THE INVENTION
The invention will now be more particularly described by way of example only with reference to various embodiments.
Example 1 is a composition which is a concentrate stable in storage but which in use is diluted with water from 200:1 to 1000:1 (i.e. 200 or 1000 parts/wt water to 1 part/wt concentrate) The composition is useful for comparing the effects of addition of various components to a Quat. biocide
EXAMPLE 1 g/ι
Benzyl dimethyl ammonium chloride, CAS 68424-85-1 150
Sodium tetraborate decahydrate, CAS 12007-42-0 30 Glycerin, CAS 56-81-5 25
Terric GN9 (note1 ) 200
Dipropylene Glycol Methyl Ether CAS 34590-94-8 100
Water balance to 1000
Note 1 : Terric GN9 is ethoxylated nonylphenol available from ORICA and is a non-ionic surfactant. Preparation
The sodium tetraborate is dissolved /suspended in the glycerol at 80°C. The quaternary biocide and Terric GN9 (non-ionic detergent) are combined with
the DPM and the pH adjusted with e.g. acetic acid to pH 7.2 - 7.3. The borate/glyce n solution is then combined with the quaternary biocide
Example 2 Example 2 is identical to example 1 but includes 0.1 % of subtilisin (0.1 % protease enzyme).
Table 1 shows MIC results obtained with various combinations of components of example 1 and example 2 in the absence of the boron and, in accordance with the invention, in the presence off the boron. In Table 1 "Quat" is an abbreviation for benzyl dimethyl ammonium chloride
TABLE 1. composition MIC, ppm MIC, ppm
(no boron) (with boron)
A
1. quat (prior art) 20 12
2 quat + DPM 16 8
3 quat + GN9 25 8
4 quat + DPM + GN9 16 <8
B
1 quat + subtilisin (0.1 % prote; ase enzyme)50 25
2 quat + DPM + enzyme 25 12
3 quat + GN9 + enzyme 25 12
4 quat + dpm + GN9 + enzyme 3 25 8
Table 1 part A compares the MIC of various quaternary ammonium biocidal compositions in the absence of boron and in the presence of boron but in the absence of protein. MIC was measured by test method described in Bailey and Scott Diagnostic Microbiology, 8th edition, 1990, p.177 using one of the most resistant to QUATs strains of Pseudomonas aeroginosa ATCC No. 15442.
Table 1 exp. 3 shows that Terric GN9 deactivates the quat. biocide as would be expected. Unexpectedly, DPM enhances the activity of a quat. even in the presence of GN9, while in each case the combination with Boron produces a marked improvement in biocidal efficacy in comparison with the combination in the absence of boron.
Table 1 part B shows the results in the presence of proteolitic enzyme subtilisin. As is apparent from the table the presence of the enzyme in the absence of boron results in a considerable reduction in efficacy of the disinfectant.
It is noteworthy that there is an improvement in efficacy of the quaternary biocide (reduction in MIC) in the presence of DPM even in the presence of the deactivator Terric GN9. However the results are significantly better with boron than without. The combination of DPM with boron synergistically improves the biocidal activity protection of the boron in comparison with compositions lacking boron or DPM (even in the presence of Terric GN9) achieving an end result of higher efficacy in the presence of the enzyme and the Terric GN9 than obtainable with the quat. biocide in the presence of 0.1% of subtilisin. in the absence of boron.
A preferred embodiment of the invention is shown in example 3. The composition of example 3 is a concentrate intended for dilution 1 part/wt concentrate in 200 parts/wt water. The composition is intended for application as a pre-soak for surgical instruments.
Example 3
Premix Borax with hot water and glycerin, add to A, adjust pH, let the mixture cool down 30°C and then slowly add premixed ingredients D. Then add water premixed with Benzalkonium Chloride 80%.
The composition is stable for at least 1 year prior to use when stored in a sealed container at 18-25 °C and when diluted with water 200:1 is biocidally effective in use for at least 24 hrs. achieving "Hospital GRADE A" disinfection
Example 4. In-surgery comparison of detergent concentrates for pre-cleaning of flexible colonoscopes.
An in-vivo evaluation was performed in a surgery randomly over a period of nine months on 105 colonoscopes after colonoscopy procedures.
Colonoscopes were soaked in 10 L of diluted 200:1 concentrates of the following detergents:
1. 15% sodium laurel sulphate + 20% Dodecyl benzene sulphonic acid at pH=9
2. 10% Dodecyl benzene sulphonic acid 10% Nonyl phenol ethoxylate (Terric GN9), 10% Alcalase 2.5 DL (subtilisin)
3. Composition described in example 3.
Total soaking time - 10 minutes. This was followed by rinsing with 10 L of sterile distilled water.
The level of bacterial contamination of: washing liquor - liquid in the bath (B) biopsy channels (C) surface of the endoscope (S) were determined by plating of the washing liquor (B),
10 mL of water syringed through the biopsy channel (C) and cotton swabs after wiping 5 sq. sm of the endoscope surface (S) of serially diluted samples onto Macconkey agar plates.
The bacterial contamination of the same parts of colonoscope and the washing liquor when instruments were soaked in sterile distilled water were used as control.
Table 2. Total bacteria counts of the contaminated surfaces on colonoscopes after soaking in detergents(statistically processed average of 105 samples, Statistical significance (t-test) was set at p<0.05):
This clearly indicates that concentrates that contain no quat. biocide only release (disperse) the bacteria and soils, creating alarmingly high bacterial contamination in cleaning baths and leaving significant amount of viable bacteria on colonoscopes. Using the present invention, one achieves a safe working environment. In the case of an instrument that is intended for contact with unbroken skin, the concentrate may be used for a one-step cleaning disinfection procedure.
THE QUAT. BIOCIDE
The invention has been exemplified by reference to alkyl benzyl dimethyl ammonium chloride (also known as benzalkonium chloride) as the highly preferred quat. biocide. However those skilled in the art will recognise that other monome c quaternary ammonium antimicrobial compounds may be used.
It is preferred that the quaternary ammonium antimicrobial compound is selected from the group having a general formula:
R'
I R'i_N-R" X I R'"
Wherein R' R" R'" R"" are alkyl radicals that may be the same or different, substituted or unsubstituted, branched or unbranched, and cyclic or acyclic. X is any anion but preferably a halogen, more preferable chlorine or bromine.
Highly preferred antimicrobial compounds are mono-long chain, tri-short chain, tetralkyl ammonium compounds, di-long-chain, di-short chain tetralkyl ammonium compounds and mixtures thereof, where by "long" chain is meant about C 6 - C 30 alkyl, and by "short" chain is meant C 1 - C 5 alkyl, preferably C1 - C 3, or benzyl, or C 1 - C 3 alkylbenzyl. Examples include monoalkyltrimethyl ammonium salts such as cetyltrimethyl ammonium bromide (CTAB), monoalkyldimethylbenzyl compounds or dialkylbenzyl compounds. Quat. biocides such as chiorhexadine gluconate may be employed. The most highly preferred compounds for use in the invention have at least one benzyl radical which may be a substituted benzyl. Examples include C 8 - C 22 dimethyl benzyl ammonium chloride , C 8 - C 22 dimethyl ethyl benzyl ammonium chloride and di- C 6 - C 20 alkyl dimethyl ammonium chloride The quaternary ammonium compound is incorporated for broad spectrum (gram positive and gram negative) antibacterial properties and should be present at least in an amount which would be effective for that purpose in the absence of protein or other deactivator. It is surprising that compositions according to the invention have excellent shelf stability both in concentrated and dilute form.
Activity Protector
According to the invention the biocidal activity of the quaternary biocide is in use protected by an "activity protector" which is a composition (an ion, compound, or combination thereof) selected from the group of known "enzyme stabilizing systems" including both reversible and irreversible enzyme inhibitors such as described in "Handbook of Enzyme Inhibitors", Zollner H., 2nd ed. VCH 1993. The preferred activity protector is a boron compound or more preferably a mixture of a boron compound and a polyol. The boron compound may for example be boric acid, boric oxide, borax, or sodium ortho-, meta-, or pyro- borate. In some formulations it may be desirable to use a perborate, such as sodium perborate to obtain a bleaching effect. The most preferred boron source
is sodium tetraborate. The protective effect of the boron compound may be enhanced by the presence of formate, or calcium ion, or by polyfunctional amino compounds such as di- or tri-ethanoiamine. Other activity protection enhancers, or adjuvants, include anions such as phosphates, citrates, sulphates and sequestering agents such as used as water softeners such as EDTA.
In systems which use boron to stabilise enzymes the addition of antioxidants and /or polyfunctional amino compounds has been reported to produce a synergistic enzyme stabilizing effect and the use of such enzyme stabilizer synergists in the present system is contemplated. The term "enzyme stabilizer systems" is used herein to denote combinations of stabilizers with enhancers, adjuvants and/or synergists and the like
Polyol The quat. biocide activity protector desirably includes a polyol.
The polyol is preferably one containing from 2 -6 hydroxyl groups and containing only C, H, and O atoms. Typical examples are ethylene glycol, propylene glycol 1 ,2 propanediol, butyleneglycol and most preferably glycerol. Other polyols such as mannitol, sorbitol, erythritol, glucose, fructose, lactose, etc may also be useful. The polyol is selected to solvate the boron and increase its ionic strength in the composition and will usually be present in an amount at least equal to the amount of boron compound.
Micelle inhibitors A water miscible solvent is desirably included to assist in solubilising the components and/or substances with which the composition comes into contact depending on its intended use and avoid or inhibit or modify micelle formation. This acts synergistically as an "activity protector" as well as apparently in some instances enhancing biocidal activity in its own right.
Preferably a water miscible solvent is selected from C1 - C 6 alkanol, C1 - C 6 diols, C3 - C 24 alkylene glycol ethers, alkylene glycol alky ethers and mixtures
thereof. A highly preferred solvent is di (propylene glycol) methyl ether. Other known micelle antagonists include borates, lactates, citrates, tartrates.
Enzymes The boron stabilizer is added in an amount required to prevent deactivation of the enzyme in the presence of protein. Surprisingly it has been found possible to include one or more enzymes in compositions according to the invention and to provide sufficient boron in the composition both to protect the quat. biocide from deactivation by the enzyme, and to protect the quat. biocide from deactivation by an additional protein (i.e. additional to the enzyme).and also to stabilise the enzymes against being denatured by the quat. It may be that a complex of the quat (e.g. with the protein) participates in reversibly protecting the enzyme. The enzymes may for example be proteolytic enzymes or selected from carbohydrases, esterases, hydrazes, amylases, proteases, catalases, lipases, amylases, cellulases, peroxidases, invertases, and the like together with mixtures thereof. The use of proteases is preferred, and of subtisilin is highly preferred.
Surfactant In preferred embodiments of the invention a surfactant is present. The surfactant is a non-ionic surfactant and it is highly preferred that it be selected from alkoxylated alcohols or alkoxylated phenol ethers or mixtures of them.
Other semipolar nonionics such as trialkyl amine oxides may also be useful.
Examples of alkoxylated phenol ethers include octyl or nonyl phenol ether with varying degrees of alkoxylation. 6 -10 moles of ethylene oxide per mole of phenol is preferred. The alkyl group can vary from C 6 - C 16 The more highly preferred are low alkoxylated nonionics having 6 -25 moles of ethylene oxide and/or propylene oxide per molecule
The alkoxylated alcohols include ethoxylated and propoxylated C 6 -C 16 alcohols with about 2 - 10 moles of ethylene oxide, or 1 -10 and 1 -10 moles of ethylene and propylene oxide per mole of alcohol respectively.
If amine oxides are used these may be mono-long chain, di-short chain, trialkylamine oxides and can be ethoxylated or propoxylated. an example is lauryl amine oxide, or cocoamidopropyldimethylamine oxide.
The quantity of surfactant is chosen so as to provide sufficient detergency for soil removal, and will typically be in the range of from 0.05% to 10% of the concentrate more preferably about 0.5% to 6% and most preferably from 2% - 4%
Treatment with the disinfectant cleaner herein described may be followed by sterilisation using heat, chemicals, or any other suitable sterilizing system.
However if sterilisation (complete kill of viable organisms) is not required, an adequate level of disinfection may be obtainable by rinsing with sterile water or other sterile solvent Hospital Grade B disinfection may be obtained merely by rinsing with sterile water after the treatment herein described.
The fact that certain monomehc quat. biocides do not require to be rinsed even from food-contacting surfaces when applied at low levels provides an opportunity to formulate single-step cleaners/disinfectants useful on certain implements for dental use, denture cleaners and the like.
The invention is herein described with particular reference to boron as the "activity protector" and quaternary ammonium biocides. It may be that not all enzyme stabilizer systems are effective as quat. biocide activity protectors, but those which are and are not effective can be determined by routine screening based upon the teaching hereof.
It will also be understood that while the invention has been described with reference to the use of quat. biocides in the cleaning bath to prevent microorganism multiplication and protect staff, the concept of including an effective biocide in the cleaning solution at a level which is at least biostatic could be practiced by use of other biocidal systems, and such systems are
within the scope of the invention herein disclosed. The invention may be embodied in many forms which will be apparent to those skilled in the arts of formulation, based upon the teaching herein contained.
Schedule 1
The TGA Disinfectant Test
This test method has been reproduced with the Idnd permission of the author and publisher from an original paper published in the "Australian Journal of Hospital Pharmacr", Vol 8, No 4; 1?78 (152-155)
1. Principle
The method, as applied to Hospital Grade Disinfectants or Sanitisers, is essentially that given by Kelsey & Maurer (1) for testing disinfectant performance. It is set out in a form suitable for attachment to a regulatory rriinimum standard for disinfectants and antiseptics. For wider application of the test refer to supplementary note A.
The disinfectant is tested at the dilution recommended by the manufacturer on the product label. The test consists of challenging the diluted disinfectant with bacterial inoculum, withdrawing a sample after a given time and culturing the sample in a suitable recovery medium. After this sampling, the mixture is again challenged by a second inoculum and after a second interval is again sampled for culturing. The sample is passed or failed according to the extent of growth shown in the two cultures sampled. The test may be performed with or without the addition of sterile yeast as an organic soil. (Options B and A respectively) or both, according to the use-situations advocated on the label of the product under test.
Table 1. Selection of test parameters for classes of disinfectant and antiseptic using the
TGA Disinfectant Test.
For Housenold Grade disinfectants, the first two organisms listed and the second cnallenge are omitted, wmle Option C (nutnent broth) is selected as the choice of simulated soil For antiseptics, the second challenge is again omitted, while Opuon D (serum) is selected as the choice of soil
Media
All media must be contained m capped glass containers Where media are stored, the containers must oe sealed tightly or refrigerated
2 1 Sterile Hard Water
2 1 1 Dissolve 0 304g anhydrous calcium chloride and 0 065g anhydrous magnesium chloride in glass-distilled water, and make up to one litre
2 1 2 DiSDense into glass containers and sterilize by autoclaving at 121° -1° C for 1 minutes
7 ? Yeast Suspension
2 2 1 Weigh 200g of moist compressed baker's yeast Cream by the gradual addition of steπle hard water usmg a heavy glass rod for stirring Decant the creamed portion into a flask, add more water to any lumpy residue remaining and repeat the creaming and decantation until no residue remains and 500ml of water has been used
2 2 2 Shake the contents of the flask vigorously and strain through a 100-mesh sieve, breaking down any remaining lumps
2 2 3 Add 500ml sterile hard water, shake vigorously and adjust the pH to 6 9- 7 1 with IN Sodium hydroxide
2 2 4 Transfer 50ml, 100ml or 200ml of the yeast solution into screw-capped bottles
2 2 5 Autoclave at 121° 1°C for 15 minutes and allow the autoclave to cool without releasing pressure Store cold but not freezing
2 2 6 Dry two Petπ dishes to constant weight Into each, pipette 25ml of sterilised yeast suspension, and dry to constant weignt at 100°C Calculate tne average solids content of the suspension
2 2 7 Before use, pipette 25ml of the sterilised yeast suspension into a beaker Determine the pH usmg the glass electrode, and determine the volume of IN sodium hydroxide solution needed to adjust the pH to within the a ge 6 9 to 7 1
/76647
-23 -
2 2 S Immediately before use, add to eacn Dottle of sterilised yeast, a volume of stenie hard water and a volume of IN sodium hydroxide calculated to adjust tne concentration of dry yeast to 5 0% and the pH to within tne range 6 9-7 1 Discard prepared yeast 3 months after preparation
Medium for Growth of Test Organisms
2 3 1 Prepare a 10% w/v dextrose solution in distilled water, and sterilise by autoclavmg at 121° 1°C for 15 minutes Cool to room temperature
2 3 2 Prepare Wπgnt and Mundy medium followmg t e author's procedure (2) or from a commercial product of the same composition (Note B) and sterilise by autoclavmg at 121° . 1°C for 15 minutes Cool to room temperature
2 3 3 To eacn litre of Wπgfit and Mundy medium prepared 2 3 2 add 10ml steπle dextrose solution prepared in 2 3 1
2 3 4 Asepticaily dispense in either 10ml or 15ml amounts, as preferred
2 3 5 This medium is referred to as Wπsht and Mundv dextrose medium
Recovery Medium
2 4 1 Prepare nutπent broth as follows or from a commercial product of the same composition (Note B) -
Add the following to 970ml of water and dissolve by heating
Beef Extract Powder lOg
Peptone lOg
Sodium Chloride 5g
Adjust the pH to 8 0-8 4 usmg IN Sodium Hydroxide Boil for 10 minutes and filter Cool
2 4 2 To each litre of nutπent broth solution prepared in 2 4 1 add 30g polysoroate 80 (Note B)
2 4 3 Adjust pH to 7 2-7 4, using IN Sodium hydroxide
2 4 4 Autoclave at 1 1° ± 1°C for 15 minutes, and immediately shake well to disperse tne polysoroate 80
2 4 5 Dispense asepticaily in 10ml amounts into steπle capped glzss tuoes
Test Inoculum
3 1 Test Organisms
The following 4 organisms are to be used, except where prescπbed Pseudomonas aeruginosa NCTC 6749 Proteus vulgaris NCTC 4635
Esc eπchia coli NCTC 8196
Staphylococc s aureus NCTC 4163
2 Preparation of Inoculum
3 2 1 Incubate the contents of an ampoule of freeze-dried culture overnight at 37° - 1°C in Wπgnt and Mundy dextrose medium.
3 2 2 Inoculate the incubated culture onto nutrient agar slopes m McCartney bottles Store for up to 3 months at 4° - 1°C
3.2 3 At a suitable period before the test is to be conducted, sub-culture from an agar slope into 10ml or 15ml quantities ofWπght and Mundy dextrose medium. Incubate at 37° - 1°C for 24 - 2 hours
3 2 *1 Sub-culture from the medium in 3 2 3 into fresh medium, using an inoculating loop of 4mm m diameter Incubate at 37° 1°C for 24 - 2 hours
3 2 5 Repeat step 3 2 4 daily. For the test procedure use only those cultures which have been sub-cultured at least 5, and not more than 14 times
3 2.6 Filter test cultures oϊP. aeruginosa and S. aureus through sterile Whatmans No 4 filter paper
3.2 7 Centrifuge all test cultures until cells are compact, and remove supernatant with a Pasteur pipette
3 2 8 Resuspend test organisms in the original volume of liquid (i e 10ml or 15ml), and shake for 1 minute with a few sterile glass beads
3 2 8 1 For Option A, resuspend in steπle hard water
3 2 8 2 For Option B, resuspend in a mixture of 4 parts yeast suspension (prepared as in 2 2) to 6 pans sterile hard water
3 2 8 3 For Option C, resuspend in nutnent broth (prepared as in 2.4 1 and 2 4 3 and steπlised by autoclavmg)
3 2 8 4 For Option D, resuspend in stenie hard water; dilute twice 1 - 9 in steπle hard water, then add 8ml of the last dilution to 2ml sheep
m,r Λ„ PCT/AU01/00381
WO 01/76647
-25 - " serum previously inactivated at 5ό°C for 20 rains, and sterilised by filtration.
3.3 Enumeration of Inoculum
Immediately before testing, sample the resuspended inoculum and enumerate using 10-fold dilutions in quarter- strength Ringer's solution and the pour-plate technique. The number subsequently counted must represent not less than 2 x 10s or more than 2 x 109 organisms per miliϋitre (or 1 x 10s - 1 x 107 using Option D) or the test is considered invalid. Retain tube containing 10'7 dilution for use in controls (7.3 and 7.4).
4. Disinfectant Dilutions
Quantitatively dilute a sample of the disinfectant to the specified extent, using sterile hard water as diluent. Use not less than 10ml or lOg of sample for the first dilution, and not less than 1ml of any dilution to prepare subsequent dilutions. Make all dilutions in glass containers on the day of testing. The glass containers must be twice rinsed in glass-distilled water, and sterilised.
5. Temperature
Where air-conditioning does not maintain test solutions at 21° ÷ 1°C, hold the containers in which the test is to be carried out in a waterbath at this temperature.
Test Procedure
Perform the following test using each of the four test organisms (3.1) except where the Standard directs otherwise. It is not necessary to test with all organisms simultaneously.
6.1 Add 3ml of diluted disinfectant to a capped glass container.
6.2 Stan a timing device. Immediately inoculate disinfectant with 1ml of culture (prepared in 3.2) and mix by swirling.
6.3 At 8 minutes, subculture one drop (0.02ml ÷ .002ml) into each of 5 tubes containing recovery broth. To ensure delivery of 0.02ml into the first tube of recovery broth at exactly 8 minutes, it will be necessary to withdraw a suitable amount from the disinfectant test mix shortly beforehand. This must be immediately preceded by vortexing. Surplus sample must be returned to the test mix. (See Note D).
6.4 Except where prescribed, at 10 minutes, inoculate disinfectant with a further 1ml of culture, and mix by vortexing.
6.5 Except where prescribed, at 18 minutes, proceed as in 6.3.
6.5 Mix the contents of all tubes of recovery broth by vortexing. Incubate at 37° ± 1°C for 48 ± 2 hours.
6.7 Examine for growth and record results.
6.S For each test organism repeat steps 6.1-6.7 on each of 2 subsequent days, using a fresh disinfectant dilution and a freshly prepared bacterial suspension.
7. Controls
7.1 Recovery broth contamination
Incubate one uninoculated tube of recovery broth at 37° ÷ 1°C for 48 ÷ 2 hours and examine for growth. If growth occurs, the test is considered invalid due to contamination of the recovery broth.
7.2 Disinfectant contamination
To 1 tube of recovery broth, add 0.02ml of diluted disinfectant. Incubate at 37° ± 1°C for 48 ± 2 hours. If growth occurs, the test is considered invalid. Growth in 7.2 but not 7.1 indicates contamination of the disinfectant test solution.
7.3 Fertility Test
To 1 tube of recovery broth, add 1.0ml of the 10" dilution retained in 3.3. Incubate at 37° ÷ 1°C for 48 ± 2 hours and examine for growth. If no growth occurs, the test is considered invalid.
7.4 Inactivator Efficacy
To 1 tube of recovery broth, add 0.02ml of diluted disinfectant and 1.0ml of the 10" dilution retained in 3.3. Incubate at 37° ± 1°C for 48 ± 2 hours, and examine for growth. If no growth occurs, the test is considered invalid. Growth in 7.3 but not in 7.4 indicates inadequate iπactivation of the disinfectant.
8. Procedure in case of invalid controls
When any control renders the test invalid, the test is to be repeated. Fresh recovery- broth is to be used if growth occurred in control 7.1 or if no growth occurred in controls 7.3 or 7.4.
Should disinfectant contamination be indicated by control 7.2 on both occasions, the disinfectant is considered to fail the test. Should inadequate inactivation of the disinfeαant be indicated by control 7.4 on both occasions, the test is considered invalid (Note C).
9. Results
The dilution test passes the test if there is no apparent growth in at least two out of the five recovery broths specified in 6.3 and no apparent growth in at least two of the five recovery broths specified in 6.5 on ail three occasions, using all four organisms.
10. References
(1) Kelsey, J.C. and Maurer Isobel, M. Pharmaceutical Journal (UK) 213 : 528- 530, (1974).
(2) Wright Eleanore, S. and Mundy, R.A. Journal of Bacteriology 80: 279-280, (1960).
1 1. Supplementary Notes
A. For investigational, developmental or comparative purposes, it will be useful to add a third challenge thus performing a true capacity test, and to test at dilutions above and below the prescribed dilution. In such cases, Kelsey & Maureris recommendations regarding the timing and organisation of the test should be carefully consulted. Abbreviations of the test may be considered for the routine test of production batches.
B. Wright & Mundy medium is commercially available as "Bacto Synthetic Broth", A.O.A.C. Code No. 0352 (Difco Ltd.). The nutrient broth to be used is available as "Nutrient Broth - No. 2" (Oxoid Ltd.).
C. Where inadequate inactivation is indicated, investigations should be conducted to find an effective inactivator. Refer Mackinnon, LH. J. Hyg (London) 73 : 189-195, (1974).
D. Pne Oxford P-7000 sampler system with disposable plastic tips is recommended for the withdrawal of samples for subculturing.
Schedule 2
Acceptable Common Names
Claims (32)
1 . A method for cleaning a contaminated medical instrument including the step of immersing the instrument in a solution containing an enzyme based cleaning composition including a "hospital grade disinfectant" (as herein defined).
2. A method according to claim 1 further including the step of sterilizing the instrument.
3. A method according to claim 1 or claim 2 further including the step of rinsing the instrument.
4. A composition for use in cleaning a contaminated medical instrument, including: an enzyme a quat biocide; and an "activity protector" as herein defined.
5. A composition according to claim 4 wherein the enzyme is selected from the group consisting of proteolytic enzymes, carbohydrases, esterases, hydrazes, amylases, proteases, catalases, Upases, amylases, cellulases, peroxidases, invertases and mixtures thereof.
6. A composition according to claim 5 including a protease.
7. A composition according to any one of claims 4 to 6 wherein the quat biocide is a monomeric quaternary ammonium antimicrobial compound selected from the group having a general formula:
R'
I R'i_N-R" X
I R"' wherein R' ,R" ,R"' ,R"" are alkyl radicals that may be the same or different, substituted or unsubstituted, branched or unbranched, and cyclic or acyclic, and
X is any anion.
8. A composition according to the preceding claim wherein X is chlorine or bromine.
9. A composition according to any one of claims 4 to 6 wherein the quat biocide is selected from the group consisting of mono-long-alkyl chain, tri-short chain, tetralkyl ammonium compounds; di-long-chain, di-short chain tetralkyl ammonium compounds and mixtures thereof.
10. A composition according to the preceding claim wherein the quat biocide is selected from the group consisting of monoalkyltrimethyl ammonium salts, monoalkyldimethylbenzyl compounds, dialkylbenzyl compounds and Quaternary gluconates.
1 1. A composition according to any one of claims 4 to 6 wherein the biocide is selected from the group consisting of C 8 to C 22 dimethyl benzyl ammonium chloride, C 8 - C 22 dimethyl ethyl benzyl ammonium chloride and di- C 6 - C 20 alkyl dimethyl ammonium chloride.
12. A composition according to any one of claims 4 to 6 wherein the quat biocide is a benzyl dimethyl ammonium haϋde.
13. A composition according to any one of claims 4 to 12 wherein the biocidal efficacy of the quat biocide is protected by an "activity protector" selected from the group consisting of "enzyme stabilizers", "enzyme stabilizing systems", "micelle formation modifiers and inhibitors", and combinations thereof.
14. A composition according to claim 13 wherein the biocidal efficacy of the quat biocide is protected by one or more enzyme stabilizers and stabilizer enhancers selected from the group consisting of boron compounds, polyols, formates, calcium ions, polyfunctional amino compounds phosphates, citrates, sulphates and sequestering agents.
15. A composition according to the preceding claim wherein a stabilizer is selected from boric acid, boric oxide, borax, or sodium ortho-, meta-, or pyro- borate and perborates.
16. A composition according to the preceding claim wherein a stabilizer includes sodium tetraborate.
17. A composition according to claim 13 wherein the biocidal efficacy of the quat biocide is protected by a boron compound and further including a polyol having from 2 to 6 hydroxyl groups.
18. A composition according to the preceding claim wherein the polyol is selected from the group consisting of ethylene glycol, propylene glycol 1 ,2 propanediol, butyleneglycol, glycerol, mannitol, sorbitol, erythritol, glucose, fructose and lactose.
19. A composition according to claim 17 wherein the polyol is selected from the group consisting of glycerol, mannitol, sorbitol, erythritol, glucose, fructose and lactose.
20. A composition according to claim 13 wherein the biocidal efficacy of the quat. biocide is protected by a micelle immiscible solvent.
21. A composition according to the preceding claim wherein the micelle immiscible solvent is selected from the group consisting of C1 - C 6 alkanols, C1 - C 6 diols, 03 - C 24 alkylene glycol ethers, alkylene glycol alky ethers, borates, lactates, citrates, tartrates and mixtures thereof.
22. A composition according to claim 21 wherein the solvent includes di
(propylene glycol) methyl ether ("DPM").
5 23. A composition according to claim 4 wherein the "activity protector" comprises boron ions.
24. A composition according to claim 4 or 23 further including DPM.
25. A composition according to any one of claims 4 to 24 further including a non ionic surfactant.
10 26. A composition according to any one of claims 4 to 25 being a shelf stable liquid disinfectant concentrate composition containing at least 1 % by weight of a quat biocide and capable of dilution with 20 parts of water to 1 part of concentrate, the diluted solution exhibiting a MIC after 24 hrs in the presence of up to 2% of tryptone (or the protein equivalent thereof) which is less than the
15 MIC of a solution of the same concentration of the same quat biocide in distilled water in the presence the same amount of the protein.
27. A composition according to claim 26 including an enzyme.
28. A composition according to claim 26 or 27 when diluted by more than 20 parts of water to 1 of concentrate. 0
29. A composition according to claim 26 or 27 when diluted by more than 100 parts of water to 1 of concentrate.
30. A composition according to claim 26 or 27 when diluted by more than 200 parts of water to 1 of concentrate.
31 . A method for cleaning a surgical instrument including the steps of immersing the instrument in a solution according to any one of claims 4 to 30, and subsequently sterilizing the instrument.
32. A method for cleaning a surgical instrument including the steps of immersing the instrument in a solution according to any one of claims 4 to 30, and subsequently rinsing with a sterile solvent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001246237A AU2001246237A1 (en) | 2000-04-07 | 2001-04-05 | Process and composition for cleaning medical instruments |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPQ6791 | 2000-04-07 | ||
AUPQ6791A AUPQ679100A0 (en) | 2000-04-07 | 2000-04-07 | Process and composition for cleaning medical instruments |
PCT/AU2001/000381 WO2001076647A1 (en) | 2000-04-07 | 2001-04-05 | Process and composition for cleaning medical instruments |
AU2001246237A AU2001246237A1 (en) | 2000-04-07 | 2001-04-05 | Process and composition for cleaning medical instruments |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001246237A1 true AU2001246237A1 (en) | 2001-10-23 |
Family
ID=3820886
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AUPQ6791A Abandoned AUPQ679100A0 (en) | 2000-04-07 | 2000-04-07 | Process and composition for cleaning medical instruments |
AU2001246237A Abandoned AU2001246237A1 (en) | 2000-04-07 | 2001-04-05 | Process and composition for cleaning medical instruments |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AUPQ6791A Abandoned AUPQ679100A0 (en) | 2000-04-07 | 2000-04-07 | Process and composition for cleaning medical instruments |
Country Status (13)
Country | Link |
---|---|
US (2) | US6762161B2 (en) |
EP (1) | EP1294410A4 (en) |
JP (1) | JP2003530447A (en) |
KR (1) | KR20030011292A (en) |
CN (1) | CN1422165A (en) |
AR (1) | AR035569A1 (en) |
AU (2) | AUPQ679100A0 (en) |
BR (1) | BR0110145A (en) |
CA (1) | CA2403920A1 (en) |
MY (1) | MY124896A (en) |
NZ (1) | NZ521495A (en) |
TW (1) | TW491713B (en) |
WO (1) | WO2001076647A1 (en) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632429B1 (en) * | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
AUPQ679000A0 (en) * | 2000-04-07 | 2000-05-11 | Novapharm Research (Australia) Pty Ltd | Biocidal protection system |
AUPQ679100A0 (en) * | 2000-04-07 | 2000-05-11 | Novapharm Research (Australia) Pty Ltd | Process and composition for cleaning medical instruments |
US20070053895A1 (en) * | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
AU2003901917A0 (en) * | 2003-04-22 | 2003-05-08 | Novapharm Research (Australia) Pty Ltd | Endoscope cleaning pad |
AU2004232373B2 (en) * | 2003-04-22 | 2010-07-29 | Novapharm Research (Australia) Pty Ltd | Endoscope cleaning pad |
NZ551868A (en) * | 2004-06-08 | 2009-07-31 | Whiteley Corp Pty Ltd | Biofilm remover |
AU2005251383C1 (en) * | 2004-06-08 | 2010-07-15 | Whiteley Corporation Pty Ltd | Biofilm remover |
DE102004035881A1 (en) * | 2004-07-23 | 2006-02-16 | Merz Pharma Gmbh & Co. Kgaa | Composition, useful for machine cleaning and disinfecting medical instrument of composite materials (e.g. flexible endoscope), comprises active substance combination of alkyldimethylammonium and protease, surfactant, water and additives |
WO2006031554A2 (en) * | 2004-09-10 | 2006-03-23 | Novozymes North America, Inc. | Methods for preventing, removing, reducing, or disrupting biofilm |
US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
EP1645195A1 (en) * | 2004-10-05 | 2006-04-12 | Basf Aktiengesellschaft | Stabilized enzyme formulations |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
US7338564B2 (en) * | 2005-12-02 | 2008-03-04 | Garman Company, Inc. | Powdered evaporator coil cleaner |
US20070207073A1 (en) * | 2006-03-03 | 2007-09-06 | Drucker Tod H | Apparatus for supporting and disinfecting a handheld instrument and/or a portion of the user's hand |
WO2007102688A1 (en) * | 2006-03-06 | 2007-09-13 | Heung-Jin Tech Corp. | Composition for deodorization and sterilization and its manufacturing process |
AR061906A1 (en) * | 2006-07-18 | 2008-10-01 | Novapharm Res Australia | LOW FOAM CLEANER |
US7541321B2 (en) * | 2006-07-26 | 2009-06-02 | Innovation Services, Inc. | Water soluble barrier film conformal coating composition |
US7198680B1 (en) * | 2006-07-26 | 2007-04-03 | Innovation Services, Inc. | Process for cleaning surfaces of medical equipment |
US7226897B1 (en) * | 2006-07-26 | 2007-06-05 | Innovation Services, Inc. | Water soluble barrier film conformal coating composition |
US7491362B1 (en) | 2008-01-28 | 2009-02-17 | Ecolab Inc. | Multiple enzyme cleaner for surgical instruments and endoscopes |
US8658163B2 (en) * | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
US8084025B2 (en) * | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
US9320780B2 (en) * | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
PL2318035T3 (en) * | 2008-07-01 | 2019-10-31 | Curemark Llc | Methods and compositions for the treatment of symptoms of neurological and mental health disorders |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
CN105031628B (en) | 2009-01-06 | 2020-10-02 | 加尔纳根有限责任公司 | Compositions and methods for treating or preventing oral infections caused by E.coli |
AU2015252099B2 (en) * | 2009-01-06 | 2017-08-10 | Galenagen, Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
KR20170005192A (en) * | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
USRE48951E1 (en) | 2015-08-05 | 2022-03-01 | Ecolab Usa Inc. | Hand hygiene compliance monitoring |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
US8172953B2 (en) * | 2009-11-06 | 2012-05-08 | Ecolab Usa Inc. | Alkyl polyglucosides and a propoxylated-ethoxylated extended chain surfactant |
US8071520B2 (en) * | 2009-11-06 | 2011-12-06 | Ecolab Usa Inc. | Sulfonated alkyl polyglucoside use for enhanced food soil removal |
US8389463B2 (en) | 2009-11-09 | 2013-03-05 | Ecolab Usa Inc. | Enhanced dispensing of solid compositions |
US8216994B2 (en) * | 2009-11-09 | 2012-07-10 | Ecolab Usa Inc. | Phosphate functionalized alkyl polyglucosides used for enhanced food soil removal |
US8888926B2 (en) * | 2010-06-08 | 2014-11-18 | Innovation Services, Inc. | Medical instrument cleaning solution and method of cleaning contaminated surfaces |
GB201010808D0 (en) * | 2010-06-28 | 2010-08-11 | Finch Stephen | Antimicrobial device for a shower |
CN101921671B (en) * | 2010-08-12 | 2013-12-11 | 陕西嘉洁医疗消毒用品有限公司 | Bio-enzyme cleaning agent for medical apparatuses and preparation method thereof |
JP5584614B2 (en) * | 2010-12-28 | 2014-09-03 | 花王株式会社 | Cleaning composition for medical equipment |
AU2012245287B2 (en) | 2011-04-21 | 2017-04-13 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
CN103087834A (en) * | 2011-11-04 | 2013-05-08 | 上海利康消毒高科技有限公司 | Pre-cleaning and moisturizing composition of medical apparatuses and method of preparing disinfectant by using same |
WO2013180136A1 (en) * | 2012-05-28 | 2013-12-05 | 花王株式会社 | Cleaning agent composition for medical-instrument cleaner |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
CN103719142B (en) * | 2012-10-10 | 2015-09-16 | 俞致健 | A kind of disinfectant and preparation method thereof and application |
WO2014079938A1 (en) * | 2012-11-26 | 2014-05-30 | Realco S.A. | Method for eliminating biofilms for cleaning medical instruments, in particular for combating nosocomial infections |
EP2789682A1 (en) * | 2013-04-12 | 2014-10-15 | Realco | Method for removing biofilms for cleaning medical instruments, in particular for controlling nosocomial infections |
US9133420B2 (en) | 2013-01-08 | 2015-09-15 | Ecolab Usa Inc. | Methods of using enzyme compositions |
BR112016003692B1 (en) | 2013-08-20 | 2022-02-08 | 3M Innovative Properties Company | POLYESTER BORO-SILANE COMPLEX |
CN104073380A (en) * | 2013-12-05 | 2014-10-01 | 成都老肯科技股份有限公司 | Multi-enzyme cleaner suitable for endoscope cleaning and preparation method thereof |
CN104073368A (en) * | 2013-12-05 | 2014-10-01 | 成都老肯科技股份有限公司 | Multi-enzyme cleaning solution suitable for hand-washing medical equipment and preparation method of multi-enzyme cleaning solution |
US20150252310A1 (en) | 2014-03-07 | 2015-09-10 | Ecolab Usa Inc. | Alkyl amides for enhanced food soil removal and asphalt dissolution |
DE102014003484A1 (en) | 2014-03-14 | 2015-09-17 | Bode Chemie Gmbh | Cleaner for inanimate surfaces with special effectiveness against mucus, secretions, blood and biofilms |
CN104233331B (en) * | 2014-09-11 | 2016-06-29 | 南京农业大学 | The sweep-out method of food rustless steel operated implement surface pathogenic bacterium biology Mycoderma |
US9907460B2 (en) | 2015-07-13 | 2018-03-06 | Michael J. Patzek, IV | Endoscope cleaning brush apparatus |
CN105296207A (en) * | 2015-12-05 | 2016-02-03 | 齐齐哈尔医学院 | Experimental utensil cleaning liquid for cytobiological and preparation method of experimental utensil cleaning liquid |
WO2017124150A1 (en) | 2016-01-22 | 2017-07-27 | Novapharm Research (Australia) Pty Ltd | Sanitising composition |
ES2906780T3 (en) * | 2016-01-28 | 2022-04-20 | Novozymes As | Method of cleaning a medical or dental instrument |
CN106010807B (en) * | 2016-06-08 | 2018-05-18 | 大连莱恩医疗工业有限公司 | A kind of multienzyme cleaning agent for stain on medical instrument |
CN106267263A (en) * | 2016-07-25 | 2017-01-04 | 合肥凯利光电科技有限公司 | The electrode disinfection treatment method of pH value of upper digestive tract dynamic monitor |
CN106367221A (en) * | 2016-08-30 | 2017-02-01 | 南京巨鲨显示科技有限公司 | Medical oil remover |
AU2018231071B2 (en) | 2017-03-07 | 2022-07-07 | Ecolab Usa Inc. | Monitoring modules for hand hygiene dispensers |
CN107549205A (en) * | 2017-08-23 | 2018-01-09 | 苏州安特实业有限公司 | A kind of composite sterilization agent and preparation method thereof |
CA3123862A1 (en) | 2018-12-20 | 2020-06-25 | Ecolab Usa Inc. | Adaptive route, bi-directional network communication |
EP3714762B1 (en) * | 2019-03-29 | 2023-08-23 | Picosun Oy | Method and apparatus for cleaning medical instruments and for detecting residue thereon |
CN111280180A (en) * | 2020-02-17 | 2020-06-16 | 四川水王子环境科技有限公司 | Potassium hydrogen peroxymonosulfate composite salt disinfection powder and preparation method thereof |
KR102229800B1 (en) * | 2020-07-24 | 2021-03-19 | (주)뉴젠사이언스 | Compositions for sterilization and disinfection comprising enzyme and the manufacturing method thereof |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0000225A1 (en) * | 1977-06-29 | 1979-01-10 | THE PROCTER & GAMBLE COMPANY | Solid detergent composition for improved greasy soil removal |
DE2967237D1 (en) * | 1978-08-10 | 1984-10-31 | Procter & Gamble Europ | Liquid detergent composition containing ternary surfactant system |
DK151397C (en) * | 1979-02-23 | 1988-08-01 | Radiometer As | PROCEDURE AND PREPARATION FOR USE IN OPERATION OF INSTRUMENTS ANALYZING PROTEIN CONTAINING BIOLOGICAL LIQUIDS |
US4507219A (en) * | 1983-08-12 | 1985-03-26 | The Proctor & Gamble Company | Stable liquid detergent compositions |
US4537706A (en) * | 1984-05-14 | 1985-08-27 | The Procter & Gamble Company | Liquid detergents containing boric acid to stabilize enzymes |
GB8530188D0 (en) * | 1985-12-06 | 1986-01-15 | Unilever Plc | Enzymatic liquid detergent composition |
US4941989A (en) * | 1986-07-16 | 1990-07-17 | Ridgely Products Co., Inc. | Cleansing and disinfecting compositions |
DE3816734A1 (en) * | 1988-05-17 | 1989-11-30 | Henkel Kgaa | METHOD FOR CLEANING AND DISINFECTING HEAT AND CORROSION-SENSITIVE MEDICAL DEVICES, ESPECIALLY ENDOSCOPES, AND MEANS FOR IMPLEMENTING THE METHOD |
CA2009118C (en) * | 1989-02-21 | 1996-02-27 | Mary F. Mowrey-Mckee | Method and composition for cleaning and disinfecting contact lenses |
DE69024323T2 (en) | 1989-10-27 | 1996-10-17 | Procter & Gamble | Antimicrobial method and formulation using Type II endoglycosidase and antimicrobial agent |
US5145643A (en) * | 1990-01-05 | 1992-09-08 | Allergan, Inc. | Nonoxidative ophthalmic compositions and methods for preserving and using same |
US5451398A (en) * | 1990-01-05 | 1995-09-19 | Allergan, Inc. | Ophthalmic and disinfecting compositions and methods for preserving and using same |
JP3243759B2 (en) * | 1990-05-09 | 2002-01-07 | アルコン ラボラトリーズ インコーポレイテッド | Antimicrobial / enzyme aqueous solution composition for cleaning and disinfecting contact lenses |
US5489531A (en) * | 1990-10-15 | 1996-02-06 | E. R. Squibb And Sons, Inc. | Combined two stage method for cleaning and decontaminating surgical instruments |
DE69220803T2 (en) * | 1991-08-21 | 1997-12-18 | Procter & Gamble | Detergent compositions containing lipase and terpene |
DE9114268U1 (en) * | 1991-11-15 | 1992-01-09 | Siemens Ag, 8000 Muenchen, De | |
US5356555A (en) * | 1992-09-14 | 1994-10-18 | Allergan, Inc. | Non-oxidative method and composition for simultaneously cleaning and disinfecting contact lenses using a protease with a disinfectant |
US5352387A (en) * | 1992-11-25 | 1994-10-04 | Lever Brothers Company | Alkyl glyceramide surfactants and compositions comprising these surfactants |
US5858117A (en) * | 1994-08-31 | 1999-01-12 | Ecolab Inc. | Proteolytic enzyme cleaner |
CN1172498A (en) * | 1994-11-18 | 1998-02-04 | 普罗格特-甘布尔公司 | Detergent compositions containing lipase and protease |
JP3420647B2 (en) * | 1994-12-15 | 2003-06-30 | 株式会社トーメー | Cleaning agent for contact lenses |
US5604190A (en) * | 1995-06-07 | 1997-02-18 | Alcon Laboratories, Inc. | Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems |
US5723421A (en) * | 1995-06-07 | 1998-03-03 | Alcon Laboratories, Inc. | Stable liquid enzyme compositions and methods of use in contact lens cleaning and disinfecting systems |
US5576278A (en) | 1995-06-07 | 1996-11-19 | Alcon Laboratories, Inc. | Stable liquid enzyme compositions and methods of use |
US5605661A (en) * | 1995-08-18 | 1997-02-25 | Alcon Laboratories, Inc. | Methods of using liquid enzyme compositions containing mixed polyols |
JPH09173426A (en) * | 1995-12-22 | 1997-07-08 | Asahi Chem Ind Co Ltd | Cleaning and disinfecting method for hydrous soft contact lens |
US5998342A (en) * | 1998-08-26 | 1999-12-07 | Cottrell International, Llc | Foaming enzyme spray cleaning composition and method of delivery |
WO2000012663A1 (en) * | 1998-09-01 | 2000-03-09 | Alcon Laboratories, Inc. | Liquid enzyme compositions for cleaning and disinfecting contact lenses |
US6010996A (en) | 1998-10-01 | 2000-01-04 | Albemarle Corporation | Biocidal surfactant compositions and their use |
WO2000026334A1 (en) * | 1998-10-30 | 2000-05-11 | Metrex Research Corporation | Simultaneous cleaning and decontaminating compositions and methods |
JP2000273489A (en) * | 1999-01-21 | 2000-10-03 | Mikimoto Pharmaceut Co Ltd | Composition for cosmetic and cleansing preservation liquid |
AUPQ679100A0 (en) * | 2000-04-07 | 2000-05-11 | Novapharm Research (Australia) Pty Ltd | Process and composition for cleaning medical instruments |
-
2000
- 2000-04-07 AU AUPQ6791A patent/AUPQ679100A0/en not_active Abandoned
-
2001
- 2001-04-05 WO PCT/AU2001/000381 patent/WO2001076647A1/en active IP Right Grant
- 2001-04-05 EP EP01918998A patent/EP1294410A4/en not_active Withdrawn
- 2001-04-05 NZ NZ521495A patent/NZ521495A/en unknown
- 2001-04-05 CN CN01807715A patent/CN1422165A/en active Pending
- 2001-04-05 AU AU2001246237A patent/AU2001246237A1/en not_active Abandoned
- 2001-04-05 JP JP2001574162A patent/JP2003530447A/en not_active Withdrawn
- 2001-04-05 KR KR1020027013351A patent/KR20030011292A/en not_active Application Discontinuation
- 2001-04-05 US US10/257,088 patent/US6762161B2/en not_active Expired - Fee Related
- 2001-04-05 BR BR0110145-5A patent/BR0110145A/en not_active IP Right Cessation
- 2001-04-05 CA CA002403920A patent/CA2403920A1/en not_active Abandoned
- 2001-04-06 MY MYPI20011662A patent/MY124896A/en unknown
- 2001-04-06 AR ARP010101667A patent/AR035569A1/en unknown
- 2001-04-06 TW TW090108328A patent/TW491713B/en not_active IP Right Cessation
-
2004
- 2004-05-12 US US10/843,759 patent/US7217684B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2403920A1 (en) | 2001-10-18 |
BR0110145A (en) | 2003-01-07 |
US20040209790A1 (en) | 2004-10-21 |
NZ521495A (en) | 2004-04-30 |
CN1422165A (en) | 2003-06-04 |
EP1294410A4 (en) | 2004-11-17 |
WO2001076647A1 (en) | 2001-10-18 |
JP2003530447A (en) | 2003-10-14 |
MY124896A (en) | 2006-07-31 |
EP1294410A1 (en) | 2003-03-26 |
US20040029752A1 (en) | 2004-02-12 |
AR035569A1 (en) | 2004-06-16 |
US6762161B2 (en) | 2004-07-13 |
AUPQ679100A0 (en) | 2000-05-11 |
KR20030011292A (en) | 2003-02-07 |
TW491713B (en) | 2002-06-21 |
US7217684B2 (en) | 2007-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6762161B2 (en) | Process and composition for cleaning medical instruments comprising protease and quaternary ammonium disinfectant | |
KR100874048B1 (en) | Biocidal protection system | |
US20210108161A1 (en) | Sanitising composition | |
AU2009243922B2 (en) | Instrument cleaner | |
EP1713520B1 (en) | Cleaning composition | |
AU2007200109A1 (en) | Process and composition for cleaning medical instruments | |
AU2001246236B2 (en) | Biocidal protection system | |
AU2001246236A1 (en) | Biocidal protection system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |